Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of PTK787 in Wet AMD
NCT00138632Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2005
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of vatalanib in exudative macular degeneration, sponsored by Novartis. Started Sep 2005; status: completed.
02
Drugs
vatalanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00138632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138632.